Table 2.
The incidence of intended bleeding pattern - defined as cycles with a withdrawal bleeding, no early or continued withdrawal bleeding, and no irregular bleeding - during NuvaRing and COC use in 1 large non-comparative study and 2 large randomized controlled trials
| Study | Method (number of participants) | Cycles with an intended bleeding pattern (%) | p value |
|---|---|---|---|
| Dieben et al 2002 | NuvaRing (n = 2322) | 63.0 | |
| Oddsson et al 2005b (13 cycles) | NuvaRing (n = 512) | 58.8–72.8 | <0.005 |
| 150LNG/30EE COC (n = 518) | 43.4–57.9 | for all cycles | |
| Milsom et al 2006 (13 cycles) | NuvaRing (n = 499) | 55.2–68.5 | <0.01 |
| DRSP/30EE COC (n = 484) | 35.6–56.6 | for all cycles |
Abbreviations: COCs, combined oral contraceptives; DRSP, drospirenone; EE, ethinyl estradiol.